New long-term data on Genentech’s groundbreaking drug for multiple sclerosis, the first approved for the most aggressive form of the condition, shows it has continued to work — and that patients who started the drug earlier got the most benefit.
Genentech will be presenting the data, which covers years’ worth of open-label extension studies of the drug, at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis in Berlin, which begins Wednesday.
The data holds “really no surprises,” said Dr. Hideki Garren, Genentech’s global head of MS and neuroimmunology. “We continue to follow these patients, so we expect to report outcomes at future congresses.”
About the Author Reprints
